Trade Advice Notice on imazapic and imazapyr in the product Sentry Herbicide for use on oats

This consultation closed on 23 December 2020.
Consultation period: 
25 November 2020 to 23 December 2020

The APVMA invites comment on the proposed use of imazapic and imazapyr in the product Sentry Herbicide for use on oats.

We invite written comment from 25 November 2020 to 23 December 2020 on the trade implications of this proposal.

The APVMA is able to consider comments relating to the legislative grounds for the assessment, which are the trade implications of the use of the product. The Trade Advice Notice provides a summary of the APVMA's residue and trade assessment.

Please note: submissions will be published on the APVMA’s website, unless you have asked for the submission to remain confidential, or if the APVMA chooses at its discretion not to publish any submissions received (refer to the public consultation coversheet).

Please lodge your submission using the public consultation coversheet, which provides options for how your submission will be published.

Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.

Please send your written submission and coversheet by email or post to:

Email: enquiries@apvma.gov.au

Post:
Executive Director, Risk Assessment Capability 
Australian Pesticides and Veterinary Medicines Authority 
GPO Box 3262 
Sydney NSW 2001

Note: A new version of the Trade Advice Notice was uploaded on the 26 November with fixes to minor typographical errors.

Submissions received

The APVMA sought comments from interested stakeholders on the proposed use of imazapic and imazapyr in the product Sentry Herbicide for use on oats, in a consultation that closed on 23 December 2020.

A total of 2 submissions were received from industry bodies.

A copy of the published submissions is available on our website.

Consultation feedback

The APVMA is currently considering all submissions received as part of this consultation.

To protect your privacy, please do not include contact information in your feedback. If you would like a response, please contact us.